Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:DMAC NASDAQ:LXEO NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.61+1.9%$1.84$1.07▼$6.18$97.12M1.162.04 million shs745,430 shsDMACDiaMedica Therapeutics$6.32-4.8%$6.51$4.01▼$10.42$340.52M0.97207,674 shs283,143 shsLXEOLexeo Therapeutics$4.31-1.8%$4.74$4.03▼$10.99$338.42M1.42952,082 shs848,644 shsXFORX4 Pharmaceuticals$4.00+1.8%$4.01$1.35▼$4.83$377.28M0.35548,959 shs875,593 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-0.32%-9.71%-13.66%+5.33%-70.30%DMACDiaMedica Therapeutics-1.48%-6.21%+1.37%+11.41%+31.23%LXEOLexeo Therapeutics-1.79%-5.79%-7.58%-22.71%+3.05%XFORX4 Pharmaceuticals-0.25%+6.50%-2.24%-4.15%+84.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.61+1.9%$1.84$1.07▼$6.18$97.12M1.162.04 million shs745,430 shsDMACDiaMedica Therapeutics$6.32-4.8%$6.51$4.01▼$10.42$340.52M0.97207,674 shs283,143 shsLXEOLexeo Therapeutics$4.31-1.8%$4.74$4.03▼$10.99$338.42M1.42952,082 shs848,644 shsXFORX4 Pharmaceuticals$4.00+1.8%$4.01$1.35▼$4.83$377.28M0.35548,959 shs875,593 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-0.32%-9.71%-13.66%+5.33%-70.30%DMACDiaMedica Therapeutics-1.48%-6.21%+1.37%+11.41%+31.23%LXEOLexeo Therapeutics-1.79%-5.79%-7.58%-22.71%+3.05%XFORX4 Pharmaceuticals-0.25%+6.50%-2.24%-4.15%+84.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50241.61% UpsideDMACDiaMedica Therapeutics 2.60Moderate Buy$12.0089.87% UpsideLXEOLexeo Therapeutics 2.89Moderate Buy$18.75335.03% UpsideXFORX4 Pharmaceuticals 2.57Moderate Buy$9.70142.50% UpsideCurrent Analyst Ratings BreakdownLatest ALDX, LXEO, XFOR, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/17/2026DMACDiaMedica Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/10/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/10/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/10/2026XFORX4 Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.007/10/2026XFORX4 Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.006/25/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026LXEOLexeo Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.006/23/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/4/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.08 per shareN/ALXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AXFORX4 Pharmaceuticals$35.11M10.75N/AN/A$2.13 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)DMACDiaMedica Therapeutics-$32.77M-$0.71N/AN/AN/AN/A-77.15%-69.23%8/11/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)Latest ALDX, LXEO, XFOR, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026LXEOLexeo Therapeutics-$0.30N/AN/AN/AN/AN/A8/11/2026Q2 2026DMACDiaMedica Therapeutics-$0.19N/AN/AN/A$13.50 millionN/A8/6/2026Q2 2026ALDXAldeyra Therapeutics-$0.11N/AN/AN/A$31.33 millionN/A8/6/2026Q2 2026XFORX4 Pharmaceuticals-$0.19N/AN/AN/A$2.42 millionN/A5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A5/6/2026Q1 2026DMACDiaMedica Therapeutics-$0.17-$0.19-$0.02-$0.19$13.50 millionN/A5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72DMACDiaMedica TherapeuticsN/A9.119.11LXEOLexeo TherapeuticsN/A14.1614.16XFORX4 Pharmaceuticals0.4510.189.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%DMACDiaMedica Therapeutics10.12%LXEOLexeo Therapeutics60.67%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics11.80%DMACDiaMedica Therapeutics5.00%LXEOLexeo Therapeutics2.00%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million53.20 millionOptionableDMACDiaMedica Therapeutics2053.88 million51.19 millionOptionableLXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataALDX, LXEO, XFOR, and DMAC HeadlinesRecent News About These CompaniesX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from AnalystsJuly 25, 2026 | marketbeat.comX4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours QuoteJuly 13, 2026 | nasdaq.comX4 Pharmaceuticals (NASDAQ:XFOR) Raised to Strong-Buy at Wells Fargo & CompanyJuly 11, 2026 | marketbeat.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 7, 2026 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 SharesJuly 2, 2026 | insidertrades.comX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsJuly 1, 2026 | globenewswire.comWhy X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.01%June 26, 2026 | aaii.comAX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comHow The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU ProgressMay 21, 2026 | finance.yahoo.comBears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' NowMay 20, 2026 | zacks.comX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowMay 18, 2026 | zacks.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comGuggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 20262 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 20263 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett | July 13, 2026ALDX, LXEO, XFOR, and DMAC Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.61 +0.03 (+1.90%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.05 (+3.17%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.DiaMedica Therapeutics NASDAQ:DMAC$6.32 -0.32 (-4.82%) Closing price 04:00 PM EasternExtended Trading$6.32 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Lexeo Therapeutics NASDAQ:LXEO$4.31 -0.08 (-1.82%) Closing price 04:00 PM EasternExtended Trading$4.31 0.00 (0.00%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.X4 Pharmaceuticals NASDAQ:XFOR$4.00 +0.07 (+1.78%) Closing price 04:00 PM EasternExtended Trading$4.00 +0.00 (+0.12%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
